Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called maraviroc in people with rheumatoid arthritis. The trial had two parts: a smaller pharmacokinetics (PK) section — which measured how the body processes the drug — involving 8 participants on a lower dose and 8 on a higher dose; and a larger proof-of-concept (POC) section, where 78 people were assigned to maraviroc 300 mg twice daily and 34 to a placebo (a dummy treatment with no active ingredient). In total, 128 people started the trial. Not everyone finished — 55 of the 77 treated maraviroc POC participants and 19 of the 33 treated placebo participants completed the study. The reported data shows that the trial measured joint symptoms using standard rheumatoid arthritis scoring systems. One measure looked at how many participants met the "ACR 20" threshold — meaning at least a 20% improvement in tender and swollen joint counts plus several other assessments. At week 8, 23 people in the maraviroc group and 7 in the placebo group met this threshold. At week 12, 8 people in the maraviroc group and 3 in the placebo group met the stricter "ACR 50" threshold (50% improvement). For the even stricter "ACR 70" threshold (70% improvement), the numbers were very small across both groups at all time points — ranging from 0 to 2 participants. The reported data also shows changes in the number of tender and swollen joints over time. For example, by week 12, the average number of tender joints had decreased by about 4.9 in the maraviroc group and 3.4 in the placebo group, while swollen joints decreased by about 3.5 and 3.4 respectively. Self-reported pain scores (on a 0–100 scale) also showed reductions in both groups across the study period, with figures not reported for a primary outcome measure in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 22251436) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Rheumatoid Arthritis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at the legal age of consent in your country
- You must have been diagnosed with active rheumatoid arthritis based on a specific set of recognized medical guidelines (the ACR 1987 Revised Criteria), with a minimum level of disease activity required to participate
- Your rheumatoid arthritis must fall within a certain range of how much it affects your daily functioning (Class I, II, or III on a standard scale — confirm with trial site)
- You must have been taking methotrexate for at least 12 weeks, with your dose staying the same for the last 4 weeks
Who may not be able to join:
- You have been diagnosed with another type of inflammatory joint disease or a secondary non-inflammatory joint condition that could affect how the study measures your disease
- You have previously been treated with certain specific medications for rheumatoid arthritis (confirm with trial site for the full list)
- You have tuberculosis or have tested positive for tuberculosis
- You have had a serious injury or major surgery in the last 2 months
- You have a history of alcohol or drug misuse outside of a defined period of being free from such use (confirm with trial site)
- You have a history of, or were found to have, low blood pressure when standing up
- You have any condition that could affect how your body absorbs medication taken by mouth
- You have a history of cancer and have been in remission for less than 3 years, or you have moderate-to-severe heart failure
- You are living with HIV, Hepatitis B or C, or have signs of any active infection
- Your blood tests, liver checks, or heart tracing (ECG) at the screening visit showed abnormal results, such as raised liver enzymes, low hemoglobin, or an irregular ECG
- You have tested positive for a specific genetic variation called the CCR5 delta 32 mutation
- You are currently taking certain medications that are not allowed in this trial (confirm with trial site for the full list)
- You are pregnant, breastfeeding, or able to have children but unwilling to use a reliable form of contraception during the trial
- You have had a serious or life-threatening infection recently, or you have severe, worsening, or uncontrollable problems with your kidneys, liver, blood, digestive system, hormones, lungs, heart, or nervous system within 12 weeks before your first dose
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
American College of Rheumatology (ACR) 20% Responders at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.